Reddit Posts
GANX — Breaking Down the GT-02287 Data. What's Actually Been Shown and What Hasn't.
Gain Therapeutics ($GANX) - The Parkinson's 'Unicorn' the biotech market is sleeping on. Clinical proof of disease reversal and a major catalyst on 3/17.
Is Gain Therapeutics about to make history at AD/PD(3/17) by becoming the first small molecule drug to repair neurons and reverse Parkinson’s?
($GANX): March Update- Evidence of Disease Modification Keeps Getting Stronger
$DDC Enterprise Announces Onboarding with Kraken to Enhance Trading and Custodian Capabilities for Bitcoin Treasury
$DDC Enterprise Announces Onboarding with Kraken to Enhance Trading and Custodian Capabilities for Bitcoin Treasury
$DDC Enterprise Announces Onboarding with Kraken to Enhance Trading and Custodian Capabilities for Btc Treasury
[Speculation] $JFB will announce a BTC Treasury Strategy
Mentions
Temporary pain and completely unjustified. No good reason. The only explanation IMO is that it phase 2 funding is still unknown. But with reduction in GluSph, and reduction in DDC, along with clinical improvement in that same group, they are showing something that no drug or therapy has shown before. A couple links you might be interested in. One is a [recent article] on GT-02287, and the other is on [biomarker DDC](https://www.drugdiscoverynews.com/new-spinal-fluid-biomarker-distinguishes-parkinson-s-and-lewy-body-dementia-from-alzheimer-s-disease-17091) which is emerging as one of the most important biomarkers in neurodegenerative disease.
If you look at just the 6 high GluSph patients they actually improved by 6 points on the UPDRS scale in 90 days. If you take out the two outliers the 11 other patients actually improved by almost 5 points. Thats excellent results. Expecting DDC biomarker data at AD/PD that could be first of its kind. https://preview.redd.it/6nnoqryruiog1.jpeg?width=1439&format=pjpg&auto=webp&s=d6fd40fff6f37347d60e45e1a6fa3684093dae17
https://preview.redd.it/o6ukkb5q4ung1.jpeg?width=1439&format=pjpg&auto=webp&s=719486cc9cfded7c43b9fcf86cf16e2472267507 The DDC biomarker being shown at AD/PD will be conclusive since the company has stated it correlates with the statistically significant data presented to date on UPDRS. Can't argue with statistically significant data if you understand the science.
Anything other than a placebo effect, except: (1) Most of the UPDRS improvements were at 90 days and not at 30 days, If placebo, why not at 30 days? (2) UPDRS improvements were almost all in the GluSph group-- why did placebo not help the others? (3) GluSph is known-- I'm not making this up-- to drive a-syn aggregation, lysosomal and mitochondrial dysfunction, and ER stress. Not sure how you see reducing it as not relevant causally. (4) In this same GluSph group that showed statistically significant improvement in UPDRS scores, DDC also improved, indicating that dopaminergic neurons are recovering or functioning better. Does this mean that this is the cure for Parkinson's? Of course not. But it is strong evidence that this sub-group is showing improvement by 90 days. A reasonable skeptical take would be: "Interesting, let's see how durable these improvements turn out to be-- looks promising, but I'm not going to take a position here."
I get the skepticism, Parkinson’s is a graveyard of failed trials. But the placebo argument hits a wall when you look at the actual biology here: Biomarkers do not have a placebo effect. A patient can feel 6 points better on a motor scale due to expectation, but a placebo does not reduce toxic brain lipids (GluSph) by 81 percent. This is the first time a drug has ever shown this level of toxin clearance in human CSF. The speculative argument doesn't hold much water. GluSph is the direct byproduct of a broken GCase enzyme, which happens to be the number one genetic risk factor for Parkinson's. Reducing it by 81 percent is definitive proof of target engagement. Basically, the drug is doing exactly what it was designed to do. Think of it as a trifecta. When you have a massive biomarker drop matching a 6 point physical gain in just 90 days, it suggests the improvement is being driven by cellular cleanup, not just a feel-good bump. Then you have the retention. 84 percent of patients stayed on for the long term extension. In a brutal disease like this, patients don't stick with extra pills unless they feel a functional difference in their daily lives. The upcoming DDC biomarker data on March 17 and 18 is the real test. If that shows neurons are actually recovering, the placebo theory is officially dead. At a 100 million dollar cap, the market is sleeping on the correlation.
The best way to look at why GT-02287 is different from the long list of failed Parkinson’s drugs is to look at the "Pipe vs. Puddle" analogy. 1. For twenty years, big pharma has been trying to mop up the "puddles"—specifically a protein called alpha-synuclein that clumps together in the brain. Drugs like Biogen’s Cinpanemab failed because by the time you’re cleaning up those clumps, the brain cells are already dying. You’re treating the symptom, not the cause. GT-02287 fixes the burst pipe. It goes "upstream" to fix a specific enzyme called GCase. When this enzyme is broken, the brain can’t clear out waste, and that’s what causes the "puddle" in the first place. By acting as a chaperone to fold that enzyme correctly, Gain is helping the brain fix its own trash disposal system. 2. In the past, we tried using large antibodies to fix Parkinson's, but they have a massive "Brain Barrier" problem. They are just too big to get into the brain in high enough concentrations to matter. GT-02287 is a small molecule. It’s designed to be taken as a pill and easily cross into the brain. Because it restores the enzyme's shape, it doesn't just do one thing—it triggers a "cellular rescue" that helps the cell's power plants (mitochondria) start working again and stops the cell from essentially "giving up" and dying. 3. We aren’t just looking at mice anymore; we have human data from the Phase 1b trial that is pretty stunning for this field: The toxin drop: In patients with high levels of toxic waste (GluSph), the drug cut those levels by 81% in just 90 days. That is the "smoking gun" that the drug is doing exactly what it was designed to do. The physicsl bounce back: These same patients saw a 6.17-point improvement in their motor scores. Usually, Parkinson’s patients just get worse every year. Seeing a 6-point improvement in three months is a massive signal that the drug is providing a real-world functional benefit. The neuron health test: The next big milestone is the DDC biomarker data coming on March 17-18. DDC tracks how well your dopamine-producing neurons are functioning. If that data is positive, it’s basically proof that we aren't just masking symptoms—we're actually saving brain cells. By fixing the pipe instead of just mopping up the puddle, Gain is tackling the disease in a way that hasn't been done successfully before.
All it takes is convincing one big pharma that it works and a deal will get done. The DDC data will be huge at AD/PD.
[**Here's a relevant paper**](https://www.nature.com/articles/s41591-026-04212-0) on DOPA decarboxylase (DDC)
The DDC biomarker is exciting. And DLB has a big overlap with Parkinson's pathology, so very relevant. BTW, DLB is a giant untapped market for disease-modification. GT-02287 might even more consistently fit a higher number of cases there than in Parkinson's.
Just read another published article yesterday showing DDC is an accurate biomarker for both PD and Lewy Body. Gains GT-02287 acts at the beginning of the problem and repairs neurons and reverses Parkinsons. Everybody else's drug works downstream and won't impact the DDC biomarker. It stands alone.
^(Docket #24-1287 / DDC /) **^(Nov 5 2025)**^(: Learning Resources, Inc. v. 'Tariffs') Black swan event ***incoming*** folks.
Keep in mind that there are plenty of other BTC treasuries that did amazing in the summer, but have been struggling for months, even though they keep stacking BTC. They likely have higher short interest Metaplanet, H100, Smarter Web, DDC
DDC went almost all in last week and commented on here around the 10s range. Not in anymore not financial advice
Anyone else in DDC? Not financial advice
Any thoughts on DDC bitcoin news? Not financial advice
I come to bring you some flowers, especially after seeing how brutal comments were on you. You got a little luck with the BTC announcement though. My question is what about AMTD excites you with DDC? Seems like AMTD has not done well since their IPO? Also any other info on what you like about this company?
DDC planning on buying btc for a reserve
DDC, halted earning release. Possible big pump, China ticket
The problem with Weight Watchers' future lies with the growing success of GLP-1 receptor agonists. While the GLP-1 tailored support program in conjunction with the Sequence acquisition did initially generate profit, it began waning quickly and projected a net loss by mid-2024. In an attempt to counter this, WW began taking advantage of GLP-1 being on the drug shortage list and started offering it to subscribers through compounding. However, GLP-1 was removed from said list in February 2025, with a temporary allowance for 503A continued compounding until April 22, 2025, and 503B until May 22, 2025. Without considering the all-but-complete shuttering the 05/22/25 date enacts, further barriers to prevent reentry have come to fruition: After Novo Nordisk petitioned the FDA to essentially disallow compounding over safety concerns, the FDA increased scrutiny via inspection requirements for cGMP compliance, and is considering GLP-1 entering the DDC list. To make matters more difficult, Novo Nordisk has taken their own private action against several 503A and 503Bs offering compounding of GLP-1. With this now drastically reduced ability to compete, the other numbers look even more concerning. WW maxed their $175m revolving credit in February 2025 on top of their already hefty $1.4b in loans/bonds that are maturing starting in 2026 through 28/29. Revenues are falling over 10%YoY and Insiders own only 0.005%. That being said, the company is by no means insolvent and thus any rumor of bankruptcy can be ignored. Galloway has even succeeded once before in the past at urging a debt restructure in place of C11 that yielded an avoidance and concurrent share price recovery. **KEY TAKEAWAY** It is my belief, based on the above information that was all taken from WW's own EDGAR filings, that WW is not worthy of long-term investment. As for short-term investment, it seems the Galloway correction has been mostly, if not completely, priced in and the stock will continue its pre-rumor downtrend. There is *some* potential over the next few days to bounce around 0.25 to 0.55 but even if they do go through with an effective non-C11 debt restructuring, those with shares now will LOSE not GAIN.
The problem with Weight Watchers' future lies with the growing success of GLP-1 receptor agonists. While the GLP-1 tailored support program in conjunction with the Sequence acquisition did initially generate profit, it began waning quickly and projected a net loss by mid-2024. In an attempt to counter this, WW began taking advantage of GLP-1 being on the drug shortage list and started offering it to subscribers through compounding. However, GLP-1 was removed from said list in February 2025, with a temporary allowance for 503A continued compounding until April 22, 2025, and 503B until May 22, 2025. Without considering the all-but-complete shuttering the 05/22/25 date enacts, further barriers to prevent reentry have come to fruition: After Novo Nordisk petitioned the FDA to essentially disallow compounding over safety concerns, the FDA increased scrutiny via inspection requirements for cGMP compliance, and is considering GLP-1 entering the DDC list. To make matters more difficult, Novo Nordisk has taken their own private action against several 503A and 503Bs offering compounding of GLP-1. With this now drastically reduced ability to compete, the other numbers look even more concerning. WW maxed their $175m revolving credit in February 2025 on top of their already hefty $1.4b in loans/bonds that are maturing starting in 2026 through 28/29. Revenues are falling over 10%YoY and Insiders own only 0.005%. That being said, the company is by no means insolvent and thus any rumor of bankruptcy can be ignored. Galloway has even succeeded once before in the past at urging a debt restructure in place of C11 that yielded an avoidance and concurrent share price recovery. **KEY TAKEAWAY** It is my belief, based on the above information that was all taken from WW's own EDGAR filings, that WW is not worthy of long-term investment. As for short-term investment, it seems the Galloway correction has been mostly, if not completely, priced in and the stock will continue its pre-rumor downtrend. There is *some* potential over the next few days to bounce around 0.35 to 0.55 but until a legitimate plan for non-C11 debt restructuring is announced, I would not bet the house on it.
2,400% up DDC with 0 volume?? The fuck DDC lol
DDC, based in Hong Kong, over 10x regular volume, up 17%. Need an AH hero
Every post I make is instantly deleted from this reddit. Just go buy DayDayCook ($DDC). Tired of this + called it [DDC regains nyse compliance](https://www.stocktitan.net/news/DDC/ddc-enterprise-regains-nyse-listing-va6ko9zhzqko.html)
They deleted all financial info when DDC and Volatus merged. Prior to the merge I am positive Volatus claimed they would be cash neutral by 2025 but I can’t find that info anymore. It was on OTC.com - $TAKOF. It looks like the next quarterly report will be issued Nov. 11.
home ownership has been in decline since the dot com bubble: [percent of americans who own homes over 100 years - Search Images (bing.com)](https://www.bing.com/images/search?view=detailV2&ccid=9r0VnBvG&id=CE711678E7B3F347F3A7463CC1C890D8DDC09E87&thid=OIP.9r0VnBvGbfQ6jYlHAqmxIQAAAA&mediaurl=https%3A%2F%2Fassets.site-static.com%2FuserFiles%2F1102%2Fimage%2Fhomeowners_vs_renters%2FHomeownership_Rates_1965-2022.jpg&cdnurl=https%3A%2F%2Fth.bing.com%2Fth%2Fid%2FR.f6bd159c1bc66df43a8d894702a9b121%3Frik%3Dh57A3diQyME8Rg%26pid%3DImgRaw%26r%3D0&exph=334&expw=474&q=percent+of+americans+who+own+homes+over+100+years&simid=608012471989203932&FORM=IRPRST&ck=FB81F1F75DAF7792300AFD0A948AF4F2&selectedIndex=3&itb=0&cw=984&ch=466&ajaxhist=0&ajaxserp=0)
I was in on DDC this morning, the reason why no oke talks about these moves is no one can predict them until its already in play I got in at 100% and sold when it was at 300%, these are rough numbers mind you. The market research I did on this company took 5 min, and that was the time it took to hit my scanners set up my trend lines find some think looks like resistance and supports and then check and see if there is news behind the pre-market moves and today they were announcing they expanded, didn't read the arrival just the headline because that is obviously going to be good news From there I waited another 15 min to make sure it was moving like I thought it would be, reset my indicators and jumped in. No where could I have really had the time to make a post saying "DDC is gonna go to the moon" I'm a pattern day trader that focuses around squeezes
That’s cool we all have our ways. I’ve found sometimes that the highs are during pre and don’t recover bc many are from AH. But if you’re checking pre pre as I say in the 4-7 trading hours you’ll see. And absolutely 20% can be made daily. It’s not about time of day, although I’ve found the 10:30 hr to be the lowest time of day I swear it’s too much how I’m running opposite of you, so keep an eye on the algos. Like DDC literally running in opposite direction as we speak. If it bounces back I’d be surprised. But it could easily be an OCEA and run for days! It’s set up perfectly.
> Drone Delivery Canada Corp. and Volatus Aerospace Corp. are both pleased to announce that they have entered into a business combination agreement to combine the companies in a merger of equals transaction, with the combined company to continue under the name "Volatus Aerospace Corp." and, continue trading under the ticker "FLT". [edited for simplicity] The new company will be called Volatus. The new company will trade under symbol FLT. > Pursuant to the Merger, Volatus shareholders will receive 1.785 Drone Delivery Canada voting common shares for each Volatus common share held. VOL shareholders will have their shares converted to FLT shares. FLT shareholders will continue to keep their shares as is. So, As a FLT shareholder, nothing will happen to your holdings other then a company name change from DDC to "Volatus".
Never heard of them, but after a quick read it seems like they are somewhat going after different markets no? DDC specifically focuses on the actual drones and deliveries, with flight software. Whereas VA seems to be more of a survey/ drone operator.
Additionally, look up Hamilton project with MIT. Solana is the crypto based on their DDC (decentralized digital currency) the future doesn’t just happen in months.